We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesBlack Diamond Therapeutics Inc

Black Diamond Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.545 USD -0.07 ( 4.04%)
Last update at 2026-11-12T15:25:00Z
VOLUME
253396
Market Cap
180.46M
P/E
8.08

Momentum Score

…

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.54
Low
1.61
High
52 Week Price Range
1.46
Low
4.94
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Black Diamond Therapeutics is a clinical-stage precision oncology company developing small-molecule therapies targeting tumor-driving genetic alterations using a proprietary discovery platform. Long-term growth drivers include clinical progress, pipeline expansion to additional mutations, and biomarker-directed development. Investors may find the company attractive for its focus on genetically defined tumor subsets and potential to address unmet needs.
Key investment risks are clinical or regulatory failure of lead candidates, high cash burn and likely need for additional financing, and intense competition in targeted oncology.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.61
Dividend Yield
-
Revenue TTM
70.00M
Revenue Per Share
1.23
Gross Profit TTM
70.00M
Debt / Equity
0.13
ROE
22.88%
Net Debt
-5.92M
ROCE
15.61%
Diluted EPS TTM
0.39

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 22.37M -69.68M -82.44M -88.92M -125.60M
Net income 22.37M -69.68M -82.44M -84.52M -123.20M
Selling general administrative 16.57M 27.47M 27.11M 28.39M 30.04M
Selling and marketing expenses - - 27.08M - -
Gross profit 69.67M -0.34M -0.44M - -
Reconciled depreciation 0.33M 0.34M 0.44M 0.51M 0.20M
Ebit 19.87M -78.78M -86.46M -92.83M -126.87M
Ebitda 20.20M -78.44M -86.02M -95.06M -125.60M
Depreciation and amortization 0.33M 0.34M 0.44M -2.23M 1.28M
Non operating income net other - - - 1.66M 1.28M
Operating income 19.87M -78.78M -86.46M -92.83M -126.87M
Other operating expenses 50.13M 78.78M 86.46M 92.83M 126.87M
Interest expense - - - -3.91M 1.28M
Interest income 4.06M 2.18M 1.92M 2.03M 3.46M
Net interest income 4.06M 2.18M 1.92M 2.03M 3.46M
Income tax expense - - - -4.40M -2.39M
Total revenue 70.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 49.80M 78.78M 86.02M 92.83M 126.87M
Cost of revenue 0.33M 0.34M 0.44M - -
Total other income expense net 2.50M 9.11M 4.02M 3.91M 1.28M
Net income from continuing ops 22.37M -69.68M -82.44M -91.17M -125.60M
Net income applicable to common shares - - - -91.17M -125.60M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 143.01M 122.64M 158.57M 156.25M 247.68M
Other current assets 3.79M 2.60M 2.63M 4.90M 5.92M
Total liab 30.80M 39.35M 41.83M 40.56M 491.50M
Total stockholder equity 112.21M 83.28M 116.74M -334.99M -243.82M
Other current liab 15.15M 13.16M 14.21M 10.54M 19.21M
Common stock 0.01M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01M
Retained earnings -464.74M -487.11M -417.43M -334.99M -243.82M
Other assets - - 0.00M 1.17M 1.24M
Cash 20.99M 36.44M 56.22M 34.31M 65.80M
Total current liabilities 15.73M 20.57M 19.65M 15.26M 23.64M
Net debt -5.92M -14.25M -30.92M -6.17M -37.34M
Short term debt - 3.40M 3.11M 2.84M 0.32M
Short long term debt total 15.07M 22.19M 25.30M 28.14M 28.46M
Other stockholder equity 576.84M 570.36M 534.19M 1.82M 0.41M
Property plant equipment - - - 2.59M 30.74M
Total current assets 132.44M 101.18M 134.03M 127.71M 209.79M
Net tangible assets - - - 115.69M 195.90M
Short term investments 107.66M 62.14M 75.18M 88.49M 143.99M
Accounts payable 0.58M 4.01M 2.32M 1.88M 4.11M
Accumulated other comprehensive income 0.10M 0.02M -0.03M -1.82M -0.41M
Common stock total equity - - - 0.01M 0.01M
Retained earnings total equity - - - -334.99M -243.82M
Non currrent assets other 0.07M 1.07M 0.82M 1.17M 7.16M
Non current assets total 10.57M 21.46M 24.53M 28.55M 37.90M
Capital lease obligations 18.78M 22.19M 25.30M 28.14M 28.46M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -44.93M 16.97M 16.35M 53.55M 133.32M
Change to liabilities - - - -8.09M 1.57M
Total cashflows from investing activities -44.91M 16.97M 16.35M 53.37M 130.61M
Total cash from financing activities -0.15M 25.55M 71.93M 0.18M 0.73M
Change to operating activities - - - -7.67M 5.45M
Net income 22.37M -69.68M -82.44M -91.17M -125.60M
Change in cash -15.44M -19.79M 21.56M -31.54M 31.19M
Begin period cash flow 37.26M 57.04M 35.48M 67.02M 35.83M
End period cash flow 21.82M 37.26M 57.04M 35.48M 67.02M
Total cash from operating activities 29.61M -62.30M -66.72M -85.08M -100.15M
Issuance of capital stock 0.00M 24.49M 71.85M - 0.00M
Depreciation 0.33M 0.34M 0.44M 0.51M 0.20M
Other cashflows from investing activities 0.07M 0.09M 0.10M 0.01M -
Sale purchase of stock - - - 0.18M 0.73M
Other cashflows from financing activities -0.15M 1.05M 0.08M 53.37M 0.73M
Change to netincome - - - 12.21M 18.22M
Capital expenditures 0.00M 0.00M 0.03M 0.19M 2.71M
Cash flows other operating - - - 0.92M -1.26M
Cash and cash equivalents changes - - - -31.54M 31.19M
Change in working capital -8.73M -2.69M 3.69M -9.90M 7.02M
Stock based compensation 6.63M 10.63M 9.60M 12.20M 14.04M
Other non cash items 9.02M -0.91M 2.00M 3.28M 2.01M
Free cash flow 29.61M -62.30M -66.75M -85.27M -102.86M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BDTX
Black Diamond Therapeutics Inc		 -0.07
4.04%		 1.54 8.08 8.33 2.58 1.56 0.93 3.21
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Black Diamond Therapeutics Inc

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

245 First Street, Cambridge, MA, United States, 02142

617 252 0848

https://www.blackdiamondtherapeutics.com

21

Name Title Year Born
Dr. David M. Epstein Ph.D. Co-Founder, Pres, CEO & Director 1959
Dr. Fang Ni Pharm.D. CFO, Principal Financial Officer and Chief Bus. Officer 1987
Mr. Brent Hatzis-Schoch Esq., J.D. COO & Gen. Counsel 1965
Dr. Elizabeth Buck Ph.D. Co-Founder & Chief Scientific Officer 1975
Ms. Erika Jones VP of Fin., Corp. Controller & Principal Accounting Officer 1985
Ms. Elizabeth L. Montgomery Chief People Officer 1972
Dr. Christopher D. Roberts Ph.D. Advisor 1970
Mr. Tai-An Lin Ph.D. Sr. VP of Translational Science & Discovery Biology NA
Dr. Sergey Yurasov M.D., Ph.D. Chief Medical Officer 1969
Ms. Melanie Morrison Sr. VP of Devel. Operations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…